OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
September 02, 2014
Annual study shows geographic proximity not a factor in CMO selection.
John Sandles, Business Analyst for Fujifilm Diosynth Biotechnologies, provided commentary on the evolving role of contract services in biologics drug development and manufacturing.
September 01, 2014
Changing regulations are impacting the identification and monitoring of variable materials in excipients.
August 04, 2014
Biopharma manufacturers must reduce the risk in their complex supply chains
August 02, 2014
Annual study shows CMO technical expertise is not enough.
Shrinking facility size, growth of biologics, and emerging market demand influence pharma investments.
August 01, 2014
Developments in chromatography column technology to deliver greater efficiency, speed and inertness benefit the drug development process from discovery to manufacturing and quality control.
Eric Langer of BioPlan Associates describes the development of biopharmaceutical outsourcing in Europe over the past 25 years.
Contract research, development, and manufacturing organizations invested in new facilities and technologies in 2014 for analytical testing, as well as small- and large-molecule drug development.
Contract service providers describe how quality by design has influenced a drug sponsor's expectations of suppliers.